Methods and apparatus for enriching for biological material from a region of interest within a tissue sample mounted on a slide using a laser apparatus are provided. A reference position of the tissue sample is defined relative to coordinates of the laser apparatus and regions of interest within the tissue sample are identified. The regions of interest are mapped to the coordinates of the laser apparatus to generate a dissection map and tissue is selectively ejected or modified using the laser apparatus to apply laser energy along a plurality of laser paths defined within the dissection map. A dissection map for one slide can be extrapolated to a dissection map for a plurality of slides bearing contiguous sections of the tissue sample using the reference position of the tissue sample on each slide.
in vivoin vivo medical imaging applications for imaging tissues or tumors expressing B1R, or in radiotherapy for treatment of a disease or condition in which B1R is expressed or overexpressed.
There is provided peptidic compounds of Formula I, A or B(Rradn6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9. Rradn6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula (I) or of a salt or a solvate thereof. R1 is —R1aR1b— wherein R1a is absent, —CH2—, —O—, or —S—, and R1b is —CH2— or —CHF—. R2 is —(CH2)3—O—, —(CH2)3—, —(CH2)4—, —CH2—O—(CH2)2—, or —CH2—S—(CH2)2. R3 is ethylene fused to a tricyclic fused ring. L1, L2, L3, L4, L5b L5c, L6 and L7 are linkages (e.g. peptide bonds). Xbr is a branching atom. Rrad is a radiometal chelator. Ralb is an albumin binder. n1, n2, n3, n4, and n5 are integers. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula (I) or of a salt or a solvate thereof. R1 is —R1aR1b— wherein R1a is absent, —CH2—, —O—, or —S—, and R1b is —CH2— or —CHF—. R2 is —(CH2)3—O—, —(CH2)3—, —(CH2)4—, —CH2—O—(CH2)2—, or —CH2—S—(CH2)2. R3 is ethylene fused to a tricyclic fused ring. L1, L2, L3, L4, L5b L5c, L6 and L7 are linkages (e.g. peptide bonds). Xbr is a branching atom. Rrad is a radiometal chelator. Ralb is an albumin binder. n1, n2, n3, n4, and n5 are integers. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.
The present invention rreellaatteess to gastrin-releasing peptide receptor (GRPR)-targeted compounds and their use for imaging and treatment of diseases or conditions characterized by expression of the gastrin-releasing peptide receptor.
Radiolabeled compounds that target fibroblast activation protein (FAP). The compounds have 1-6 radiolabeling groups and 1-6 FAP-targeting groups, connected by 1-11 linkers. FAP-targeting groups have the structure of Formula (I). R1a and R1b are each —H, —OH, halogen, C1-6 alkyl, —O—C1-6 alkyl, or —S—C1-6 alkyl. R2 is —NH—, —N(CH3)—, —CH2—, —CH(OH)—, —CHF—, —CF2—, —S—, or —O—. R3 is —CO2H, —C(O)NH2, —CN or —B(OH)2. R4 is —H, methyl, or ethyl. R5 is ═O. R6 is —C(O)—, —O—C(O)—, or —NH—C(O)—. n4 is 0, 1, 2, or 3. R7 is an 11 to 15-membered aromatic, partially aromatic, or non-aromatic fused tricyclic system, wherein the tricyclic system is optionally contains 1-6 heteroatoms selected from N, O, and/or S, and is optionally substituted. There is also provided the use of such compounds as imaging agents or therapeutic agents. Formula (I).
Radiolabeled compounds that target fibroblast activation protein (FAP). The compounds have 1-6 radiolabeling groups and 1-6 FAP-targeting groups, connected by 1-11 linkers. FAP-targeting groups have the structure of Formula (I). R1a and R1b are each —H, —OH, halogen, C1-6 alkyl, —O—C1-6 alkyl, or —S—C1-6 alkyl. R2 is —NH—, —N(CH3)—, —CH2—, —CH(OH)—, —CHF—, —CF2—, —S—, or —O—. R3 is —CO2H, —C(O)NH2, —CN or —B(OH)2. R4 is —H, methyl, or ethyl. R5 is ═O. R6 is —C(O)—, —O—C(O)—, or —NH—C(O)—. n4 is 0, 1, 2, or 3. R7 is an 11 to 15-membered aromatic, partially aromatic, or non-aromatic fused tricyclic system, wherein the tricyclic system is optionally contains 1-6 heteroatoms selected from N, O, and/or S, and is optionally substituted. There is also provided the use of such compounds as imaging agents or therapeutic agents. Formula (I).
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
Antimicrobial peptides (AMPs) exhibiting broad spectrum antimicrobial activity are described. Such peptides are useful in treating or preventing infections and other conditions, and are of special interest for treating antibiotic-resistant bacterial pathogens, viruses, fungi, and other pathogens, or for anti-cancer applications. Treatment or prevention of infection in humans or animals is described as well as uses and methods for disinfecting or prevention of growth of microbes on a surface, a material, or in an environment, such as for environmental remediation. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. Two high throughput bioinformatics approaches leading to (1) de novo design of numerous antimicrobial peptides, and (2) identification of numerous antimicrobial peptides from known genomic sequences are described.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61L 2/16 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p. ex. liaison anticorps-antigène, liaison récepteur-ligand
C40B 30/06 - Procédés de criblage des bibliothèques en mesurant les effets sur des cellules, des tissus ou des organismes vivants
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
8.
METHOD AND APPARATUS FOR PARENT-OF-ORIGIN DISEASE ALLELE DETECTION FOR THE DIAGNOSIS AND MANAGEMENT OF GENETIC DISEASES
A method of assigning parent-of-origin to a haplotype, a sub-haplotype or an allele associated with a haplotype. Chromosome-length haplotypes of a genome are generated and a differential methylation status of at least one imprinted differentially methylated region (iDMR) associated with each one of the autosomal chromosomes is determined. The differential methylation status of the at least one iDMR is used to assign parent-of-origin for each one of the chromosome-length haplotypes.
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
G16B 30/10 - Alignement de séquenceRecherche d’homologie
9.
COMPOSITIONS AND METHODS FOR INHIBITION OF CASP3 AND CASP7 FOR CANCER THERAPY
Methods of using inhibition of CASP3 and CASP7 to treat cancer are provided. CASP3 and CASP7 inhibition can be synthetic lethal with lack of expression of functional proteins involved in homologous recombination, DNA damage response pathways, splicing, or mitotic DNA damage checkpoint signaling. CASP3 and CASP7 inhibition can also be lethal to cells when combined with a second therapeutic such as a DNA damaging agent, an autophagy-inducing agent, a proteasome inhibitor, a PARP inhibitor, an EGFR inhibitor, an ERK inhibitor, or an MEK inhibitor. Non-canonical p29 and p30 fragments of CASP7 can be used as a biomarker for prognosis or to determine if a cancer is likely to respond to treatment using inhibition of CASP3 and CASP7. Inhibition of CASP3 and CASP7 can also treat cancer in certain contexts in which resistance to PARP inhibitors has developed by inhibiting PARP1.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
10.
BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS
Compounds having a structure of Formula I:
Compounds having a structure of Formula I:
Compounds having a structure of Formula I:
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
C07D 295/088 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'oxygène ou de soufre liés par des liaisons simples avec les atomes d'azote du cycle et les atomes d'oxygène ou de soufre liés à la même chaîne carbonée, qui n'est pas interrompue par des carbocycles à une chaîne acyclique saturée
A61K 31/09 - Éthers ou acétals ayant une liaison éther à un carbone cyclique d'un noyau aromatique ayant plusieurs liaisons éther
A61K 31/145 - Amines, p. ex. amantadine ayant des atomes de soufre, p. ex. thiurames (N-C(S)-S-C(S)-N ou N-C(S)-S-S-C(S)-N)Sulfinylamines (-N=SO)Sulfonylamines (-N=SO2)
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07C 43/23 - Éthers une liaison sur l'oxygène de la fonction éther étant sur un atome de carbone d'un cycle aromatique à six chaînons contenant des groupes hydroxyle ou O-métal
C07C 69/28 - Esters d'acides acycliques monocarboxyliques saturés dont le groupe carboxyle est lié à un atome de carbone acyclique ou à l'hydrogène avec au moins trois atomes de carbone dans la partie acide estérifiés par des composés dihydroxylés
C07C 233/18 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons simples avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone acyclique ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné acyclique saturé
C07C 311/04 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé ayant les atomes d'azote des groupes sulfonamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone acycliques de radicaux hydrocarbonés substitués par des atomes d'oxygène liés par des liaisons simples
C07C 311/51 - Y étant un atome d'hydrogène ou de carbone
C07C 317/18 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des groupes sulfone ou sulfoxyde liés à des atomes de carbone acycliques du squelette carboné
C07C 317/22 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des groupes sulfone ou sulfoxyde liés à des atomes de carbone de cycles aromatiques à six chaînons du squelette carboné
C07C 317/28 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au même squelette carboné avec des groupes sulfone ou sulfoxyde liés à des atomes de carbone acycliques du squelette carboné
C07D 233/60 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre, liés aux atomes d'azote du cycle
11.
RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY
C07K 7/54 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 14/665 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains dérivés de pro-opiomélanocortine, pro-enképhaline ou pro-dynorphine
12.
ANALYZER SYSTEM AND METHOD FOR REAL-TIME SYNCHRONOUS DETECTION OF THE CHARACTERISTIC NEAR-INFRARED WAVELENGTH FEATURES OF OPTICALLY ACTIVE SUBSTANCES
An optical system and methods have been developed for real-time synchronous detection of vibration and/or rotation modes in biotic (e.g., fat, glyceride, vitamins, bilirubin, etc.) and abiotic systems (e.g., alcohol contents). The system and methods include a modulated light source (e.g., a CW laser of 1064 nm wavelength modulated at square wave signal at 5600 Hz by a square wave signal), laser beam shaping and light collecting optics, optical detectors, appropriately selected optical filters, mechanical or electronic laser beam modulator, electrical signal amplifiers (e.g., transimpedance, current and voltage amplifiers), synchronous detector (e.g. lock-in amplifier), data acquisition and hardware and software control systems. One or multiple lock-in amplifiers are used to extract weak signals from noisy background. The system has three configurations/embodiments for in-situ and ex-situ end uses—(i) tabletop probe, (ii) handheld probe and (iii) miniature handheld probe. The handheld probe is for ex-situ and open surgery whereas the tabletop probe can be combined with other systems for ex-situ (monitoring) assessments. The miniature handheld probe can be used in conjunction with needle biopsies. The weak signal of characteristic optical scattering (e.g., Raman scattering) peaks of target biotic indicators (e.g., glyceride, vitamins, bilirubin, etc.) and abiotic molecules (e.g., alcohol) are identified using sensitive lock-in amplification technique, which supersedes the state-of-the-art for other similar approaches and allows for the detection of weak Raman signals in ambient light conditions (e.g., LED and luminescent light). Without restricting the generality of the present disclosure, the system has been shown to provide a quantitative result of the fat content quickly and accurately in (i) lipid phantoms and (ii) liver samples, demonstrating a strong linear correlation (e.g., r>0.98) between output voltage signals and fat contents in the clinically relevant range.
A synthetic platform for detecting epitopes that are recognized by cytotoxic lymphocytes from a plurality epitopes presented by antigen-presenting reporter cells. In one aspect, apoptosis of antigen-presenting reporter cells is delayed to increase a safe sorting window for the reporter cells. Apoptosis of the antigen-presenting reporter cells can be delayed by one or more of expressing one or more anti-apoptotic proteins in the reporter cells, knocking down expression of one or more pro-apoptotic proteins in the reporter cells, or knocking down expression of granzyme or perforin in the cytotoxic lymphocytes. In one aspect, surviving antigen-presenting reporter cells may be washed and proliferated prior to being exposed again to the cytotoxic lymphocytes. The cytotoxic lymphocyte can be an immortalized cell line derived from a T-cell or a natural killer cell.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 5/078 - Cellules du sang ou du système immunitaire
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
C40B 40/02 - Bibliothèques contenues ou présentées dans des micro-organismes, p. ex. des bactéries ou des cellules animalesBibliothèques contenues ou présentées dans des vecteurs, p. ex. des plasmidesBibliothèques contenant uniquement des micro-organismes ou des vecteurs
C40B 50/06 - Procédés biochimiques, p. ex. utilisant des enzymes ou des micro-organismes viables entiers
14.
IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS
The present invention relates to radiolabeled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of the gastrin-releasing peptide receptor (GRPR). The compounds comprise a radiolabeling group and a plurality of amino acids linked by peptide bonds. In preferred embodiments the radiolabeling group is a chelating group, such as 1,4,7,10-tetraazacyclododecane- 1,4, 7,10- tetraacetate (DOTA) which is conjugated with a radionuclide, such as gallium-68 (68Ga). The compounds are useful as diagnostic agents and as therapeutic agents, and may be used for the diagnosis and treatment of cancer.
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
15.
HYDROXYPHENYL-ETHYNYL-PHENOL DERIVATIVES AS AR (ANDROGEN RECEPTOR) TRANSCRIPTIONAL ACTIVITY MODULATORS FOR USE IN THE TREATMENT OF I.A. PROSTATE CANCER
FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (Espagne)
UNIVERSITAT DE BARCELONA (Espagne)
INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (Espagne)
PROVINCIAL HEALTH SERVICES AUTHORITY (Canada)
Inventeur(s)
Salvatella Giralt, Xavier
Riera Escalé, Antoni
Frigolé Vivas, Marta
Sánchez Zarzalejo, Carolina
Ruffoni, Alessandro
Verdaguer Espaulella, Francesc Xavier
Sadar, Marianne Dorothy
Banuelos, Carmen Adriana
Mawji, Nasrin
Abrégé
The present invention relates to compounds of formula (I) and their use for modulating the transcriptional activity of the androgen receptor and its splice variants for treating various indications including prostate cancer
The present invention relates to compounds of formula (I) and their use for modulating the transcriptional activity of the androgen receptor and its splice variants for treating various indications including prostate cancer
A method for detecting a presence of at least one constituent of an analyte gas is based on Raman scattering. The method comprises: mixing a buffer gas with the analyte gas; exciting the mixture with a laser excitation beam; detecting scattered photons resulting from interaction between photons of the laser excitation beam and molecules of the analyte gas to thereby determine a spectral content of the scattered photons; and analyzing the spectral content to determine the presence of the at least one constituent.
A device may obtain first information relating to one or more first lung nodules identified in first imaging of a chest of a patient and second information relating to one or more second lung nodules identified in second imaging of the chest of the patient. The device may provide the first information and the second information to a machine learning model. The device may determine, using the machine learning model, a risk of lung cancer associated with the patient based on an elapsed time between performance of the first imaging and the second imaging and differences between the first information and the second information. The risk of lung cancer may have an inverse correlation to the elapsed time and a direct correlation to the differences. The device may perform one or more actions based on the risk of lung cancer that is determined.
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
18.
RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY
A compound is provided comprising a melanocortin 1 receptor (MC1R) targeting peptide (MC1RTP), a radiolabeling group, and a linker joining the MC1RTP to the radiolabeling group. The MC1RTP is linear or cyclized, and comprises a sequence of Formula I or Formula II: Xaa1-Xaa2a-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7a (I) or Xaa1-Xaa2b-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7b (I). Xaa1 is L- /D-Nle, L-/D-Nle, L-/D-Ala, L-/D-Leu, L-/D-Ile, D-Ile, L-/D-Cys, L-/D-Met, L-/D-Phe, L-/D-Trp, L-/D-Val, L-/D-Nal, L-/D-2-Nal, Gly, L-/D-α-aminobutryic acid, L-/D-norvaline, or L-/D-homonorleucine. Xaa2a and Xaa7b are L-/D-Cys, L-/D-Asp, L-/D-Glu, L-/D-2-Aad, L-/D-3-Aad, L-/D-Pra, L-/D-Hpg, or L-/D-Bpg. Xaa2b and Xaa7a are L-/D-Cys, L-/D-Lys, L-/D-Orn, L-/D-Dab, L-/D-Dap, L-/D-Lys(N3), L-/D-Om(N3), L-/D-Dab(N3), L-/D-Dap(N3), L-/D-2-(5′-azidopentyl)alanine, or L-/D-2-(6′-azidohexyl)alanine. Xaa3 is L-/D-His, Pro, beta-(1,2,3-triazol-4-yl)-L-alanine, beta-(1,2,3-triazol-4-yl)-D-alanine, 1,2,4-triazole-3-alanine, or 1,2,4-triazole-3-D-N alanine. Xaa4 is L-/D-Phe, L-/D-2-Nal, L-/D-Phe(4-F), L-/D-Phe(4-Cl), L-/D-Phe(4-Br), L-/D-Phe(4-I), L-/D-Phe(4-NH2), or L-/D-Phe(4-NO2). Xaa5 is L-/D-Arg, L-/D-hArg), Leu, L-/D-Agb, or L-/D-Agp. Xaa6 is L-/D-Trp, L-/D-Phe, L-/D-Trp(5-Br), L-/D-Trp(5-OCH3), L-/D-Trp(6-F), L-/D-Trp(5-OH) or L-/D-Trp(CHO). One or more amino acid residues of the MC1RTP is alpha N-methylated, wherein 1, 2, 3 or 4 of Xaa3, Xaa5, Xaa6 and Xaa7a is alpha N-methylated or wherein 1, 2, 3 or 4 of Xaa3, Xaa5, Xaa6 and Xaa2b is alpha N-methylated. The linker comprises an albumin-binding group.
A61K 47/08 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'oxygène
The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.
Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion proteins and conjugates of the present disclosure are also provided, as are methods of using such compositions, e.g., for therapy, in vivo imaging and/or the like. In certain aspects, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual, wherein the individual comprises cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cells by VV B5 antigens expressed on the surface of the infected cells.
Antimicrobial peptides (AMPs) exhibiting broad spectrum antimicrobial activity are described. Such peptides are useful in treating or preventing infections and other conditions, and are of special interest for treating antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach leading to identification of numerous antimicrobial peptides from known genomic sequences is described.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C12N 15/12 - Gènes codant pour des protéines animales
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p. ex. liaison anticorps-antigène, liaison récepteur-ligand
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
A fiber optic imaging system generates multipath image data. The system comprises: an optical coherence tomography (OCT) system comprising an OCT fiber optically connected to an interferometric detector; a multi-clad fiber (MCF) for receiving sampled light that has interacted with a sample and propagating the sampled light as a fundamental MCF mode and one or more higher order MCF modes; and an optical joint for coupling the sampled light from the MCF into the OCT fiber, the optical joint configured to couple at least some light energy from both the fundamental MCF mode and the one or more higher order MCF modes into a fundamental mode of the OCT fiber where the at least some light energy propagates as OCT return light.
Described herein are methods and compositions for selective activation of cells using variant cytokine receptor and cytokine pairs, wherein the cytokine receptors comprise an extracellular domain (ECD) of granulocyte-colony stimulating factor receptor (G-CSFR). In certain embodiments, the methods and compositions described herein are useful for exclusive activation of cells for adoptive cell transfer therapy. Thus, included herein are methods of producing cells expressing variant receptors that are selectively activated by a cytokine that does not bind its native receptor. Also disclosed herein are methods of treating a subject in need thereof, comprising administering to the subject cells expressing an variant receptor comprising an extracellular domain of G-CSFR and co-administering a variant cytokine that activates the variant receptor.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula.
The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula: (II)
The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula: (II)
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/5386 - 1,4-Oxazines, p. ex. morpholine condensées en spiro ou formant une partie de systèmes cycliques pontés
A61K 31/541 - Thiazines non condensées contenant d'autres hétérocycles
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
A system useful for in vivo and ex vivo spectroscopy comprises a water source connected to supply water through a passage to an outlet at a flow rate sufficient to issue a laminar water jet from the outlet, a light source operative to emit a light beam that is guided to a sample by the water jet, and an analysis unit connected to receive collected light that has been emitted from the sample into the water jet and operable to analyze the collected light. Some embodiments provide endoscopes with integrated light guides.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G01N 21/3563 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de solidesPréparation des échantillons à cet effet
Disclosed is a method and system for determining at least one set of plurality of paths to a target zone comprising receiving at a processor, at least one image representing a target zone, providing an elongate introduction region extending along an axis and extending therearound by a radius to the target zone, utilizing the processor, defining at least one non- intersecting trajectory path through the introduction region and extending into the target zone and outputting a representation of the plurality of trajectory paths. The definition of trajectory path is implemented by using the first target locations, iteratively grouping the successive sites using centroidal veronoi tessellations into a predetermined quantity of successive target locations; and defining a best fit line between each successive target location with its corresponding first target location.
G05B 19/402 - Commande numérique [CN], c.-à-d. machines fonctionnant automatiquement, en particulier machines-outils, p. ex. dans un milieu de fabrication industriel, afin d'effectuer un positionnement, un mouvement ou des actions coordonnées au moyen de données d'un programme sous forme numérique caractérisée par des dispositions de commande pour le positionnement, p. ex. centrage d'un outil par rapport à un trou dans la pièce à usiner, moyens de détection additionnels pour corriger la position
A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
A61M 36/10 - Application utéro-vaginale ou pelvienne
28.
FAP2-DERIVED ANTIBODIES AND VACCINES AGAINST FUSOBACTERIUM
A new composition of matter composed of engineered sequences for the expression of Fap2-derived polypeptides that provoke immunogenic responses against Fusobacterium spp. is provided. Antibodies and vaccines produced using such sequences and methods of use are also provided.
Described herein are chimeric receptors comprising G-CSFR extracellular domains and the intracellular domains of various multi-subunit cytokine receptors for selective activation of cytokine signaling in cells of interest. In certain aspects, the selective activation of cytokine signaling in cells expressing the chimeric receptors described herein includes the ability to specifically stimulate adoptively transferred cells.
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
Described herein are methods and compositions for selective activation of cells using variant cytokine receptor and cytokine pairs, wherein the cytokine receptors comprise an extracellular domain (ECD) of granulocyte-colony stimulating factor receptor (G-CSFR). In certain embodiments, the methods and compositions described herein are useful for exclusive activation of cells for adoptive cell transfer therapy. Thus, included herein are methods of producing cells expressing variant receptors that are selectively activated by a cytokine that does not bind its native receptor. Also disclosed herein are methods of treating a subject in need thereof, comprising administering to the subject cells expressing an variant receptor comprising an extracellular domain of G-CSFR and co-administering a variant cytokine that activates the variant receptor.
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
32.
Method for parent-of-origin disease allele detection for the diagnosis and management of genetic diseases
A method of assigning parent-of-origin to a haplotype, a sub-haplotype or an allele associated with a haplotype. Chromosome-length haplotypes of a genome are generated and a differential methylation status of at least one imprinted differentially methylated region (iDMR) associated with each one of the autosomal chromosomes is determined. The differential methylation status of the at least one iDMR is used to assign parent-of-origin for each one of the chromosome-length haplotypes.
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
G16B 30/10 - Alignement de séquenceRecherche d’homologie
The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.
The present disclosure relates to prostate specific membrane antigen (PSMA)-targeting compounds of formula (I) or of a salt or a solvate thereof. The PSMA-targeting compounds of the present disclosure can be useful as imaging agents for PSMA-expressing diseases/conditions.
The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
C07C 235/78 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné avec des atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques d'un squelette carboné non saturé le squelette carboné contenant des cycles
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
PROVINCIAL HEALTH SERVICES AUTHORITY (Canada)
Inventeur(s)
Dimitrov, Dimiter Stanchev
Baek, Dusan
Chu, Xiaojie
Sorensen, Poul H.
Abrégé
This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to an ENPP1 polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to an ENPP1 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer (e.g., one or more sarcomas) are provided.
Methods and apparatus for segmenting cell nuclei in medical images apply first and second trained machine learning algorithms. The first trained machine learning algorithm processes a medical image to provide center locations of cell nuclei depicted in the image. The second machine learning algorithm processes each of a plurality of patches of the image. Each of the patches correspond to one of the plurality of center locations. Processing each patch yields a nuclear boundary corresponding to the corresponding one of the center locations. The methods and apparatus allow associating individual pixels of the image with one or more than one nuclei and have been shown to be effective for instance segmentation of nuclei in clusters of overlapping cell nuclei.
G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras
G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
39.
METHOD AND APPARATUS FOR PARENT-OF-ORIGIN DISEASE ALLELE DETECTION FOR THE DIAGNOSIS AND MANAGEMENT OF GENETIC DISEASES
A method of assigning parent-of-origin to a haplotype, a sub-haplotype or an allele associated with a haplotype. Chromosome-length haplotypes of a genome are generated and a differential methylation status of at least one imprinted differentially methylated region (iDMR) associated with each one of the autosomal chromosomes is determined. The differential methylation status of the at least one iDMR is used to assign parent-of-origin for each one of the chromosome-length haplotypes.
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
Provided are compounds and method for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat disease, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Compounds provided are of Formula (I).
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
This application relates to compounds of Formula (I-a) or Formula (I-b), or is salts or solvates thereof. R1 is —(CH2)5CH3 or comprises 2-4 fused benzene rings. R2 is I, Br, F, Cl, H, OH, OCH3, NH2, NO2 or CH3. R3 is a peptide-bonded glycine, aspartate or glutamate or is glutamate peptide bonded through Cdelta. L is —CH2NH—, —(CH2)2NH—, —(CH2)3NH—, or —(CH2)4NH—. R4 is a radiometal chelator optionally bound by a radiometal. Variable ‘n’ is 1-3. The compounds may be useful for imaging prostate specific membrane antigen (PSMA)-expressing tissues or for treating PSMA-expressing diseases (e.g. cancer).
This application relates to compounds of Formula (I-a) or Formula (I-b), or is salts or solvates thereof. R1 is —(CH2)5CH3 or comprises 2-4 fused benzene rings. R2 is I, Br, F, Cl, H, OH, OCH3, NH2, NO2 or CH3. R3 is a peptide-bonded glycine, aspartate or glutamate or is glutamate peptide bonded through Cdelta. L is —CH2NH—, —(CH2)2NH—, —(CH2)3NH—, or —(CH2)4NH—. R4 is a radiometal chelator optionally bound by a radiometal. Variable ‘n’ is 1-3. The compounds may be useful for imaging prostate specific membrane antigen (PSMA)-expressing tissues or for treating PSMA-expressing diseases (e.g. cancer).
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, A-III, A- IV, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
C07K 7/02 - Peptides linéaires contenant au moins une liaison peptidique anormale
C07K 7/56 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle cyclisés autrement que par l'acide diamino-2,4 butanoïque
44.
CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME
The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, A-III, A- IV, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.
C07K 7/56 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle cyclisés autrement que par l'acide diamino-2,4 butanoïque
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
There is provided peptidic compounds of Formula I, A or B(Rrad n6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8--Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or Me-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2Thz, or Thz. represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9.Rrad n6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.
There is provided peptidic compounds of Formula I, A or B(Rradn6n6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa922). Xaa1is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2is Asn, Gln, Hse, Cit or His. Xaa3is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4is Ala or Ser. Xaa5is Val, Cpg, or Tle. Xaa6is Gly, NMe-Gly, or D-Ala. Xaa7is His or NMe-His. Xaa8is Leu or Phe. Xaa9222Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8to Xaa9.Rradn6n6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.
Seattle Children's Hospital (dba Seattle Children's Research Institute) (USA)
Provincial Health Services Authority (Canada)
University of Pittsburgh - of the Commonwealth System of Higher Education (USA)
Inventeur(s)
Orentas, Rimas J.
Dimitrov, Dimiter Stanchev
Sorensen, Poul H.
Zhang, Haifeng
Li, Wei
Abrégé
Some embodiments provided herein also include methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to an IL1RAP polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to an IL1RAP polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided. Some embodiments of the methods and compositions provided herein include chimeric antigen receptors (CARs) which specifically bind to interleukin-1 receptor accessory protein (IL1RAP). Some embodiments include nucleic acids encoding such CARs, and cells containing such CARs. Some embodiments include the use of such CARs in safe and effective therapies for a cancer, such as an IL1RAP-expressing cancer, such as a Ewing's sarcoma and acute myeloid leukemia (AML).
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
48.
RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula (I) or of a salt or a solvate thereof. R1 is –R1aR1b– wherein R1a is absent, –CH2–, –O–, or –S–, and R1b is –CH2– or –CHF–. R2 is –(CH2)3–O–, –(CH2)3–, –(CH2)4–, –CH2–O–(CH2)2–, or –CH2– S–(CH2)2. R3 is ethylene fused to a tricyclic fused ring. L1, L2, L3, L4, L5b, L5c, L6 and L7 are linkages (e.g. peptide bonds). Xbr is a branching atom. Rrad is a radiometal chelator. Ralb is an albumin binder. n1, n2, n3, n4, and n5 are integers. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
C07K 7/02 - Peptides linéaires contenant au moins une liaison peptidique anormale
49.
RADIOLABELED COMPOUNDS TARGETNG THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula (I) or of a salt or a solvate thereof. R1is –R1aR1b– wherein R1a22–, –O–, or –S–, and R1b22– or –CHF–. R22323242222222. R3is ethylene fused to a tricyclic fused ring. L1, L2, L3, L4, L5b, L5c, L6and L7are linkages (e.g. peptide bonds). Xbris a branching atom. Rradis a radiometal chelator. Ralb is an albumin binder. n1, n2, n3, n4, and n5 are integers. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
50.
CHELATOR COMPOSITIONS FOR RADIOMETALS AND METHODS OF USING SAME
A chelator having the general structure (I) for chelating ra-diometals such as 225Ac under mild conditions is provided. (I) The chelator can be coupled to a biological targeting moiety to facilitate targeted delivery of the chelated radiometal in a mammalian subject.
C07D 273/00 - Composés hétérocycliques contenant des cycles comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle, non prévus par les groupes
An optical system and methods have been developed for real-time synchronous detection of vibration and/or rotation modes in biotic (e.g., fat, glyceride, vitamins, bilirubin, etc.) and abiotic systems (e.g., alcohol contents). The system and methods include a modulated light source (e.g., a CW laser of 1064 nm wavelength modulated at square wave signal at 5600 Hz by a square wave signal), laser beam shaping and light collecting optics, optical detectors, appropriately selected optical filters, mechanical or electronic laser beam modulator, electrical signal amplifiers (e.g., transimpedance, current and voltage amplifiers), synchronous detector (e.g. lock-in amplifier), data acquisition and hardware and software control systems. One or multiple lock-in amplifiers are used to extract weak signals from noisy background. The system has three configurations/embodiments for in-situ and ex-situ end uses – (i) tabletop probe, (ii) handheld probe and (iii) miniature handheld probe. The handheld probe is for ex-situ and open surgery whereas the tabletop probe can be combined with other systems for ex-situ (monitoring) assessments. The miniature handheld probe can be used in conjunction with needle biopsies. The weak signal of characteristic optical scattering (e.g., Raman scattering) peaks of target biotic indicators (e.g., glyceride, vitamins, bilirubin, etc.) and abiotic molecules (e.g., alcohol) are identified using sensitive lock-in amplification technique, which supersedes the state-of-the-art for other similar approaches and allows for the detection of weak Raman signals in ambient light conditions (e.g., LED and luminescent light). Without restricting the generality of the present disclosure, the system has been shown to provide a quantitative result of the fat content quickly and accurately in (i) lipid phantoms and (ii) liver samples, demonstrating a strong linear correlation (e.g., r > 0.98) between output voltage signals and fat contents in the clinically relevant range.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
Radiolabeled compounds that target fibroblast activation protein (FAP). The compounds have 1-6 radiolabeling groups and 1-6 FAP-targeting groups, connected by 1-11 linkers. FAP-targeting groups have the structure of Formula (I). R1aand R1b1-61-61-61-6 alkyl. R23222-, -S-, or -O-. R32222. R4is -H, methyl, or ethyl. R5is =O. R6is -C(O)-, -O-C(O)-, or -NH-C(O)-. n4 is 0, 1, 2, or 3. R7 is an 11 to 15-membered aromatic, partially aromatic, or non-aromatic fused tricyclic system, wherein the tricyclic system is optionally contains 1-6 heteroatoms selected from N, O, and/or S, and is optionally substituted. There is also provided the use of such compounds as imaging agents or therapeutic agents. Formula (I).
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
54.
HYDROXYPHENYL-ETHYNYL-PHENOL DERIVATIVES AS AR (ANDROGEN RECEPTOR) TRANSCRIPTIONAL ACTIVITY MODULATORS FOR USE IN THE TREATMENT OF I.A. PROSTATE CANCER
INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (Espagne)
UNIVERSITAT DE BARCELONA (Espagne)
FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (Espagne)
PROVINCIAL HEALTH SERVICES AUTHORITY (Canada)
Inventeur(s)
Salvatella Giralt, Xavier
Riera Escale, Antoni
Frigole Vivas, Marta
Sanchez Zarzalejo, Carolina
Ruffoni, Alessandro
Verdaguer Espaulella, Francesc Xavier
Sadar, Marianne Dorothy
Banuelos, Carmen Adriana
Mawji, Nasrin
Abrégé
The present invention relates to compounds of formula (I) and their use for modulating the transcriptional activity of the androgen receptor and its splice variants for treating various indications including prostate cancer
HYDROXYPHENYL-ETHYNYL-PHENOL DERIVATIVES AS AR (ANDROGEN RECEPTOR) TRANSCRIPTIONAL ACTIVITY MODULATORS FOR USE IN THE TREATMENT OF I.A. PROSTATE CANCER
FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (Espagne)
UNIVERSITAT DE BARCELONA (Espagne)
INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (Espagne)
PROVINCIAL HEALTH SERVICES AUTHORITY (Canada)
Inventeur(s)
Salvatella Giralt, Xavier
Riera Escalé, Antoni
Frigolé Vivas, Marta
Sánchez Zarzalejo, Carolina
Ruffoni, Alessandro
Verdaguer Espaulella, Francesc Xavier
Sadar, Marianne Dorothy
Banuelos, Carmen Adriana
Mawji, Nasrin
Abrégé
The present invention relates to compounds of formula (I) and their use for modulating the transcriptional activity of the androgen receptor and its splice variants for treating various indications including prostate cancer
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be —CO2H, —SO2H, —SO3H, —PO2H, or —PO3H2, for example. R2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be —CO2H, —SO2H, —SO3H, —PO2H, or —PO3H2, for example. R2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.
FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (Espagne)
UNIVERSITAT DE BARCELONA (Espagne)
INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (Espagne)
PROVINCIAL HEALTH SERVICES AUTHORITY (Canada)
Inventeur(s)
Salvatella Giralt, Xavier
Riera Escalé, Antoni
Frigolé Vivas, Marta
Sánchez Zarzalejo, Carolina
Ruffoni, Alessandro
Verdaguer Espaulella, Francesc Xavier
Sadar, Marianne Dorothy
Banuelos, Carmen Adriana
Mawji, Nasrin
Abrégé
The present invention relates to compounds of formula (I) and their use for modulating the transcriptional activity of the androgen receptor and its splice variants for treating various indications including prostate cancer
The present disclosure relates to DNA-PK inhibiting compounds and prodrugs thereof that are useful in the treatment of diseases, including cancer. In particular, the compounds sensitise cancers to therapies such as chemotherapy and radiotherapy.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
A system useful for in vivo and ex vivo spectroscopy comprises a water source connected to supply water through a passage to an outlet at a flow rate sufficient to issue a laminar water jet from the outlet, a light source operative to emit a light beam that is guided to a sample by the water jet, and an analysis unit connected to receive collected light that has been emitted from the sample into the water jet and operable to analyze the collected light. Some embodiments provide endoscopes with integrated light guides.
A61B 1/07 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement utilisant des moyens conduisant la lumière, p. ex. des fibres optiques
G01J 3/02 - SpectrométrieSpectrophotométrieMonochromateursMesure de la couleur Parties constitutives
A system useful for in vivo and ex vivo spectroscopy comprises a water source connected to supply water through a passage to an outlet at a flow rate sufficient to issue a laminar water jet from the outlet, a light source operative to emit a light beam that is guided to a sample by the water jet, and an analysis unit connected to receive collected light that has been emitted from the sample into the water jet and operable to analyze the collected light. Some embodiments provide endoscopes with integrated light guides.
G01J 3/02 - SpectrométrieSpectrophotométrieMonochromateursMesure de la couleur Parties constitutives
A61B 1/07 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement utilisant des moyens conduisant la lumière, p. ex. des fibres optiques
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G01J 3/44 - Spectrométrie RamanSpectrométrie par diffusion
Provided are antibodies that specifically bind Vaccinia Virus (VV) A56 or B5 antigen. Also provided are fusion proteins and conjugates that comprise the antibodies. Pharmaceutical compositions and kits that comprise the antibodies, fusion proteins and conjugates are also provided. Aspects of the present disclosure further include methods of using the antibodies, fusion proteins and conjugates, e.g., for therapeutic purposes. In certain embodiments, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual having cancer, wherein the individual comprises cancer cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cancer cells by VV antigens expressed on the surface of the infected cancer cells. Aspects of the present disclosure further include methods of targeting an antibody, fusion protein, or conjugate that specifically binds an oncolytic virus (OV) antigen to cancer cells in an individual.
Described herein are methods and compositions for selective activation of cells using variant cytokine receptor and cytokine pairs, wherein the cytokine receptors comprise an extracellular domain (ECD) of granulocyte-colony stimulating factor receptor (G-CSFR). In certain embodiments, the methods and compositions described herein are useful for exclusive activation of cells for adoptive cell transfer therapy. Thus, included herein are methods of producing cells expressing variant receptors that are selectively activated by a cytokine that does not bind its native receptor. Also disclosed herein are methods of treating a subject in need thereof, comprising administering to the subject cells expressing an variant receptor comprising an extracellular domain of G-CSFR and co-administering a variant cytokine that activates the variant receptor.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
C07K 14/535 - CSF du type granulocyteCSF du type granulocyte-macrophage
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
Described herein are methods and compositions for selective activation of cells using variant cytokine receptor and cytokine pairs, wherein the cytokine receptors comprise an extracellular domain (ECD) of granulocyte-colony stimulating factor receptor (G-CSFR). In certain embodiments, the methods and compositions described herein are useful for exclusive activation of cells for adoptive cell transfer therapy. Thus, included herein are methods of producing cells expressing variant receptors that are selectively activated by a cytokine that does not bind its native receptor. Also disclosed herein are methods of treating a subject in need thereof, comprising administering to the subject cells expressing an variant receptor comprising an extracellular domain of G-CSFR and co-administering a variant cytokine that activates the variant receptor.
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
C07K 14/535 - CSF du type granulocyteCSF du type granulocyte-macrophage
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
The invention described herein is based in part on the discovery of a protein/peptide crosslink, which introduces fluorescent properties, and which has been applied to synthesize analogues of melanocortin and amanitin as choice peptides to be explored in the context of isoindole peptides. Without limitation, it is expected that those trained in the art of peptide synthesis and stapling would appreciate the consequences of this invention such that other peptides of varied length can be similarly constrained by isoindole staples as featured herein.
C07K 7/56 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle cyclisés autrement que par l'acide diamino-2,4 butanoïque
C07K 14/72 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des hormones
A61K 38/00 - Préparations médicinales contenant des peptides
65.
ANTI-VACCINIA VIRUS ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion proteins and conjugates of the present disclosure are also provided, as are methods of using such compositions, e.g., for therapy, in vivo imaging and/or the like. In certain aspects, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual, wherein the individual comprises cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cells by VV B5 antigens expressed on the surface of the infected cells.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
Provided are antibodies that specifically bind to Vaccinia Virus B5 antigen (VV B5). In certain embodiments, the anti-VV B5 antibodies are humanized antibodies. Fusion proteins and conjugates comprising such antibodies are also provided. Pharmaceutical compositions comprising the antibodies, fusion proteins and conjugates of the present disclosure are also provided, as are methods of using such compositions, e.g., for therapy, in vivo imaging and/or the like. In certain aspects, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual, wherein the individual comprises cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cells by VV B5 antigens expressed on the surface of the infected cells.
C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
67.
7-MORPHOLINO-1,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR
The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula: (II)
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/5386 - 1,4-Oxazines, p. ex. morpholine condensées en spiro ou formant une partie de systèmes cycliques pontés
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
Antigen targeting agents that target brachyury as restricted and presented by MHC proteins are provided. The antigen targeting agent can be a T-cell, CAR construct, antibody, bi-specific antibody, or the like. Methods of treating cancers involving expression or overexpression of brachyury and methods of screening for patients likely to benefit from such treatment are provided. A novel tumor-associated antigen comprising a brachyury peptide presented by HLA-C*04:01 is provided.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
69.
7-MORPHOLINO-1,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR
The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula: (II)
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/5386 - 1,4-Oxazines, p. ex. morpholine condensées en spiro ou formant une partie de systèmes cycliques pontés
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p. ex. liaison anticorps-antigène, liaison récepteur-ligand
A device may obtain first information relating to one or more first lung nodules identified in first imaging of a chest of a patient and second information relating to one or more second lung nodules identified in second imaging of the chest of the patient. The device may provide the first information and the second information to a machine learning model. The device may determine, using the machine learning model, a risk of lung cancer associated with the patient based on an elapsed time between performance of the first imaging and the second imaging and differences between the first information and the second information. The risk of lung cancer may have an inverse correlation to the elapsed time and a direct correlation to the differences. The device may perform one or more actions based on the risk of lung cancer that is determined
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
74.
NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER
This application relates to compounds of Formula I. R1a, R1b and R1c is —CO2H, —SO2H, —SO3H, —SO4H, —PO2H, —PO3H or —PO4H. R2 is a linker, e.g. butylene. R3 is a linkage, e.g. —O—, —S—, —S(O)—, S(O)2—, —NHC(O)—, —C(O)NH—, or 1,2,3-triazole. R4 is —(CH2)0-3CH(R7)(CH2)0-3— wherein R7 is —(CH2)5CH3 or certain aromatic fused-ring systems. R5 and R6 are hydrogen or methyl. Each Xaa1 (if present) is an amino acid. RX is a radiolabeling group, e.g.: a radiometal chelator optionally bound by a radiometal; an aryl substituted with a radioisotope; a prosthetic group containing a trifluoroborate; or a prosthetic group containing a silicon-fluorine-acceptor moiety. The compounds may be useful for imaging prostate-specific membrane antigen (PSMA)-expressing tissues or for treating PSMA-expressing diseases (e.g. cancer).
This application relates to compounds of Formula I. R1a, R1b and R1c is —CO2H, —SO2H, —SO3H, —SO4H, —PO2H, —PO3H or —PO4H. R2 is a linker, e.g. butylene. R3 is a linkage, e.g. —O—, —S—, —S(O)—, S(O)2—, —NHC(O)—, —C(O)NH—, or 1,2,3-triazole. R4 is —(CH2)0-3CH(R7)(CH2)0-3— wherein R7 is —(CH2)5CH3 or certain aromatic fused-ring systems. R5 and R6 are hydrogen or methyl. Each Xaa1 (if present) is an amino acid. RX is a radiolabeling group, e.g.: a radiometal chelator optionally bound by a radiometal; an aryl substituted with a radioisotope; a prosthetic group containing a trifluoroborate; or a prosthetic group containing a silicon-fluorine-acceptor moiety. The compounds may be useful for imaging prostate-specific membrane antigen (PSMA)-expressing tissues or for treating PSMA-expressing diseases (e.g. cancer).
Methods and apparatus for segmenting cell nuclei in medical images apply first and second trained machine learning algorithms. The first trained machine learning algorithm processes a medical image to provide center locations of cell nuclei depicted in the image. The second machine learning algorithm processes each of a plurality of patches of the image. Each of the patches correspond to one of the plurality of center locations. Processing each patch yields a nuclear boundary corresponding to the corresponding one of the center locations. The methods and apparatus allow associating individual pixels of the image with one or more than one nuclei and have been shown to be effective for instance segmentation of nuclei in clusters of overlapping cell nuclei.
An antigen targeting agent is provided. The antigen targeting agent binds to a mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) protein having a missense mutation at position 12 when a peptide incorporating the missense mutation is presented by an HLA-A*02 molecule. The missense mutation at position 12 of the KRAS protein may be G12D, G12V or G12C. The antigen targeting agents can be used diagnostically or for immunotherapy.
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
77.
SEQUENTIAL CONVOLUTIONAL NEURAL NETWORKS FOR NUCLEI SEGMENTATION
Methods and apparatus for segmenting cell nuclei in medical images apply first and second trained machine learning algorithms. The first trained machine learning algorithm processes a medical image to provide center locations of cell nuclei depicted in the image. The second machine learning algorithm processes each of a plurality of patches of the image. Each of the patches correspond to one of the plurality of center locations. Processing each patch yields a nuclear boundary corresponding to the corresponding one of the center locations. The methods and apparatus allow associating individual pixels of the image with one or more than one nuclei and have been shown to be effective for instance segmentation of nuclei in clusters of overlapping cell nuclei.
This application relates to compounds of Formula (I): [targeting peptide]-N(R1)—X1(R2)L1-[linker]-RXn1 (I). The targeting peptide is cyclo[L-Phe-L-Tyr-L-Lys(iPr)-D-Arg-L-2-Nal-Gly-D-Glu]-L-Lys(iPr). R1 is H or methyl. X1 is an optionally substituted C1-C15 hydrocarbon optionally comprising heteroatoms. R2 is C(O)OH or C(O)NH2. L1 is a linkage (thiolether, amide, maleimide-thiol, triazole). The linker has a net negative charge at physiological pH and is a linear or branched chain of 1-10 units of X2L2 and/or X2(L2)2, wherein: each X2 is, independently, an optionally substituted C1-C15 hydrocarbon optionally comprising heteroatoms; and each L2 is a linkage. The linker optionally further comprises an albumin binder bonded to an L2. Each RX is a radiolabelling group linked through a separate L2, selected from: a metal chelator; a prosthetic group containing trifluoroborate (BF3); or a prosthetic group containing a silicon-fluorine-acceptor moiety. The compounds may be useful for imaging CXCR4-expressing tissues or for treating CXCR4-associated diseases or conditions (e.g. cancer).
The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor N-terminal domain inhibitor or an inhibitor and a second therapeutically active agent, such as an CDK4/6 inhibitor, a Pin1 inhibitor (inhibitor of peptidyl-prolyl cis/trans isomerases), or an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer. Further, the present disclosure relates administering an androgen receptor N-terminal domain inhibitor in combination with radiation therapy for treatment of various cancers.
A61K 31/145 - Amines, p. ex. amantadine ayant des atomes de soufre, p. ex. thiurames (N-C(S)-S-C(S)-N ou N-C(S)-S-S-C(S)-N)Sulfinylamines (-N=SO)Sulfonylamines (-N=SO2)
The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
C07K 5/037 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale la liaison anormale étant formée par la chaîne latérale d'un alpha-amino-acide, p. ex. gamma-Glu, epsilon-Lys, glutathion
81.
RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
C07K 5/037 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale la liaison anormale étant formée par la chaîne latérale d'un alpha-amino-acide, p. ex. gamma-Glu, epsilon-Lys, glutathion
A chelating agent having the general formula (I) is provided (I) Metal chelates and constructs for carrying out targeted radionuclide therapy incorporating such chelating agents are provided. Methods of making and using the chelating agent, metal chelates and constructs for carrying out targeted radionuclide therapy, as well as diagnostic and therapeutic methods using such constructs, are provided.
A chelating agent having the general formula (I) is provided (I) Metal chelates and constructs for carrying out targeted radionuclide therapy incorporating such chelating agents are provided. Methods of making and using the chelating agent, metal chelates and constructs for carrying out targeted radionuclide therapy, as well as diagnostic and therapeutic methods using such constructs, are provided.
Lymphocytes having a suppressed autophagy gene useful in immunotherapy are disclosed. The lymphocytes can express an antigen targeting receptor such as a chimeric antigen receptor (CAR) or endogenous or engineered T-cell receptor to target cells expressing a tumor-specific antigen. Methods of making and using such lymphocytes are disclosed. Some such lymphocytes are useful in conducting CAR-T or TCR-T therapy.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire
The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.
A compound or molecular complex. The compound or molecular complex comprises: a metal chelator configured for chelation with a radioactive isotope or a non-radioactive isotope; and a trifluoroborate (BF3)-containing moiety configured for 19F/18F exchange or a precursor thereof; and optionally a cell-targeting domain.
A61K 47/08 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'oxygène
Methods and apparatus for obtaining 3D imaging of tissue involve scanning a focused laser beam in xz planes to obtain a set of xz plane images spaced apart in a y direction. The xz plane images are processed to correct distortions and motions and combined to provide 3D image data. Surface flatting is optionally performed. Imaging may be performed using a femtosecond (fs) laser beam. Different components of light returning from the tissue may be detected and processed to yield plural co-registered images using different imaging modalities, for example, reflective confocal microscopy (RCM), two photon fluorescence (TPF) and second harmonic generation (SHG).
The present invention relates to gene expression profiles for B-cell lymphoma. More specifically, the present invention relates to gene expression profiles for diagnosis, prognosis or therapy selection for an aggressive B-cell lymphoma.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
92.
RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS
There is provided bombesin-derived compounds of Formula Ia (RX-L-Xaa1-Gln-Trp-Ala-Val-Xaa2-His-Xaa3-ψ-Xaa4-NH2). RX comprises a radionuclide chelator or a trifluoroborate-containing prosthetic group. L is a linker. Xaa1 is D-Phe, Cpa (4-chlorophenylalanine), D-Cpa, Tpi (2,3,4,9-tetrahydro-1H-pyrido[3,4b]indol-3-carboxylic acid), D-Tpi, Nal (naphthylalanine), or D-Nal. Xaa2 is Gly, N-methyl-Gly or D-Ala. Xaa3 is Leu, Pro, D-Pro, or Phe. Xaa4 is Pro, Phe, Tac (thiazolidine-4-carboxylic acid), Nle (norleucine), 4-oxa-L-Pro (oxazolidine-4-carboxylic acid). The symbol ψ represents a reduced peptide bond between Xaa3 and Xaa4 in which ψ is CH2—N when Xaa4 is Pro, Tac or 4-oxa-L-Pro, or ψ is CH2N(R) when Xaa4 is Phe or Nle wherein R is H or C1-C5 linear or branched alkyl. There is also provided the use of such compounds as imaging agents or therapeutic agents.
Compounds having a structure of Formula I:
11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
C07D 295/088 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'oxygène ou de soufre liés par des liaisons simples avec les atomes d'azote du cycle et les atomes d'oxygène ou de soufre liés à la même chaîne carbonée, qui n'est pas interrompue par des carbocycles à une chaîne acyclique saturée
A61K 31/09 - Éthers ou acétals ayant une liaison éther à un carbone cyclique d'un noyau aromatique ayant plusieurs liaisons éther
A61K 31/145 - Amines, p. ex. amantadine ayant des atomes de soufre, p. ex. thiurames (N-C(S)-S-C(S)-N ou N-C(S)-S-S-C(S)-N)Sulfinylamines (-N=SO)Sulfonylamines (-N=SO2)
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07C 43/23 - Éthers une liaison sur l'oxygène de la fonction éther étant sur un atome de carbone d'un cycle aromatique à six chaînons contenant des groupes hydroxyle ou O-métal
C07C 69/28 - Esters d'acides acycliques monocarboxyliques saturés dont le groupe carboxyle est lié à un atome de carbone acyclique ou à l'hydrogène avec au moins trois atomes de carbone dans la partie acide estérifiés par des composés dihydroxylés
C07C 233/18 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons simples avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone acyclique ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné acyclique saturé
C07C 311/04 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé ayant les atomes d'azote des groupes sulfonamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone acycliques de radicaux hydrocarbonés substitués par des atomes d'oxygène liés par des liaisons simples
C07C 311/51 - Y étant un atome d'hydrogène ou de carbone
C07C 317/18 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des groupes sulfone ou sulfoxyde liés à des atomes de carbone acycliques du squelette carboné
C07C 317/22 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des groupes sulfone ou sulfoxyde liés à des atomes de carbone de cycles aromatiques à six chaînons du squelette carboné
C07C 317/28 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au même squelette carboné avec des groupes sulfone ou sulfoxyde liés à des atomes de carbone acycliques du squelette carboné
C07D 233/60 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre, liés aux atomes d'azote du cycle
94.
Radiolabeled compounds targeting the prostate-specific membrane antigen
3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
95.
BINDERS AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN
SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) (USA)
UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
PROVINCIAL HEALTH SERVICES AUTHORITY (Canada)
Inventeur(s)
Orentas, Rimas J.
Dimitrov, Dimiter Stanchev
Sorensen, Poul H.
Zhang, Haifeng
Li, Wei
Abrégé
Some embodiments provided herein also include methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to an IL1RAP polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to an IL1RAP polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided. Some embodiments of the methods and compositions provided herein include chimeric antigen receptors (CARs) which specifically bind to interleukin-1 receptor accessory protein (IL1RAP). Some embodiments include nucleic acids encoding such CARs, and cells containing such CARs. Some embodiments include the use of such CARs in safe and effective therapies for a cancer, such as an IL1RAP-expressing cancer, such as a Ewing's sarcoma and acute myeloid leukemia (AML).
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) (USA)
PROVINCIAL HEALTH SERVICES AUTHORITY (Canada)
UNIVERSITY OF PITTSBURGH – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Orentas, Rimas J.
Dimitrov, Dimiter Stanchev
Sorensen, Poul H.
Zhang, Haifeng
Li, Wei
Abrégé
Some embodiments provided herein also include methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and/or ADC) to an IL1RAP polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and/or ADCs) that bind to an IL1RAP polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided. Some embodiments of the methods and compositions provided herein include chimeric antigen receptors (CARs) which specifically bind to interleukin-1 receptor accessory protein (IL1RAP). Some embodiments include nucleic acids encoding such CARs, and cells containing such CARs. Some embodiments include the use of such CARs in safe and effective therapies for a cancer, such as an IL1RAP-expressing cancer, such as a Ewing's sarcoma and acute myeloid leukemia (AML).
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
97.
CHELATOR COMPOSITIONS FOR RADIOMETALS AND METHODS OF USING SAME
A chelator having the general structure (I) for chelating radiometals such as 225Ac under mild conditions is provided. The chelator can be coupled to a biological targeting moiety to facilitate targeted delivery of the chelated radiometal in a mammalian subject
A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
C07D 273/00 - Composés hétérocycliques contenant des cycles comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle, non prévus par les groupes
98.
CHELATOR COMPOSITIONS FOR RADIOMETALS AND METHODS OF USING SAME
A chelator having the general structure (I) for chelating radiometals such as 225Ac under mild conditions is provided. (I) The chelator can be coupled to a biological targeting moiety to facilitate targeted delivery of the chelated radiometal in a mammalian subject.
C07D 273/00 - Composés hétérocycliques contenant des cycles comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle, non prévus par les groupes
Systems for confocal Raman spectroscopy of points of interest or regions of interest with concurrent imaging are disclosed. The imaging may be used for real time selection of points of interest or regions of interest for Raman spectroscopy and to monitor for unwanted motions of a sample while Raman spectra are acquired. Disclosed embodiments apply Reflectance confocal microscopy (RCM) in a confocal Raman spectroscopy system. A single laser may be used as a light source for both RCM and micro-Raman spectroscopy. A Faraday optical isolator may be applied to extract RCM signals for imaging Systems as described herein have example application for ex vivo sample and in vivo skin measurement.
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Computer software for tracking, managing and analyzing injuries in the workplace (1) Computer services, namely, providing online access to computer software for tracking, managing and analyzing injuries in the workplace
